Pyrazole appended quinoline-BODIPY based arene ruthenium complexes: their anticancer activity and potential...

Area of Science:

• Organometallic Chemistry
• Medicinal Chemistry
• Photodynamic Therapy

Background:

• Development of novel metal complexes for cancer therapy.
• Ruthenium complexes as promising anticancer agents.
• BODIPY-based ligands for targeted drug delivery.

Purpose of the Study:

• Synthesize and characterize new arene ruthenium complexes with BODIPY ligands.
• Evaluate the photophysical, electrochemical, and biological properties of these complexes.
• Assess their potential as theranostic agents for cancer treatment.

Main Methods:

• Synthesis and characterization of ruthenium complexes and BODIPY ligands.
• X-ray crystallography for structural determination.
• Photophysical, electrochemical, DNA binding, cytotoxicity, cellular uptake, and apoptosis assays.
• Singlet oxygen generation studies and molecular docking.
• In vitro antiproliferative and photocytotoxicity evaluation against HeLa cells.

Main Results:

• Successfully synthesized and characterized four new arene ruthenium complexes.
• Complexes exhibit significant photocytotoxicity against HeLa cells under visible light, with low dark toxicity.
• Demonstrated preferential accumulation in HeLa cell lysosomes and potential theranostic capabilities.
• Photocytotoxicity order: 4 > 3 > 2 > 1.

Conclusions:

• The synthesized ruthenium-BODIPY complexes are highly effective photocytotoxic agents against human cervical cancer cells.
• These complexes show promise as theranostic agents due to their targeted action and minimal dark toxicity.
• Further investigation into their therapeutic potential is warranted.